These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33633748)

  • 1. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease.
    Lambrecht J; Tacke F
    Front Immunol; 2020; 11():634409. PubMed ID: 33633748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.
    Leung HH; Puspanathan P; Chan AW; Nik Mustapha NR; Wong VW; Chan WK
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1131-1138. PubMed ID: 35362158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating miRNAs associated with nonalcoholic fatty liver disease.
    Atic AI; Thiele M; Munk A; Dalgaard LT
    Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging biomarkers of NAFLD, NASH, and fibrosis.
    Ajmera V; Loomba R
    Mol Metab; 2021 Aug; 50():101167. PubMed ID: 33460786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
    Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
    Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
    du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
    Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.
    Albhaisi S; Sanyal AJ
    Pharmaceut Med; 2019 Dec; 33(6):451-463. PubMed ID: 31933238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.